EMDR Treatment in PTSD Following Cardiac Events

Summary

Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.

Conditions

• Posttraumatic Stress Disorder
• Myocardial Infarction
• Eye Movement Desensitization and Reprocessing

Interventions

BEHAVIORAL

EMDR Treatment

Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.

Sponsors & Collaborators

• EMDR Europe

  collaborator INDUSTRY

• Stiftung zur Förderung von Psychiatrie und Psychotherapie

  collaborator UNKNOWN

• EMDR Foundation

  collaborator UNKNOWN

• EMDO Stiftung

  collaborator UNKNOWN

• University of Zurich

  lead OTHER

Principal Investigators

• Christoph Mueller-Pfeiffer, PD Dr. med. · University of Zurich/University Hospital Zurich

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-11-21

Primary Completion

2027-11-30

Completion

2027-11-30

Countries

• Switzerland

Study Locations